Fact-checked by Grok 2 weeks ago

Johnson & Johnson Vision

Vision is a division of MedTech dedicated to addressing global needs through innovative eye care products and surgical solutions, serving over 44 million people annually. The division focuses on tackling major eye health challenges, including the global epidemic of affecting more than 2 billion people, with 1 billion cases preventable or unaddressed, and projections of a 50% increase by 2030. It offers a range of consumer and professional products, such as the ACUVUE® brand of prescription contact lenses designed for conditions like (affecting over 2 billion people globally as of 2020), (over 1 billion), and (about 1 in 3 people). Surgical innovations include intraocular lenses for treatment—the leading cause of blindness in most countries among adults over 40—and correction procedures like iLASIK, alongside therapies for dry eye disease, particularly impacting over 340 million worldwide. As part of MedTech's portfolio, which emphasizes precision technologies for complex health issues, the segment plays a strategic role in advancing less invasive, personalized eye care to improve at every stage.

Company Overview

Formation and Scope

Johnson & Johnson Vision was formally established in 2017 following Johnson & Johnson's $4.325 billion acquisition of Medical Optics (AMO), a leading eye care company, which was subsequently rebranded and integrated with the parent company's existing vision care operations. This move consolidated expertise in , creating a unified entity dedicated to eye health. The division's roots in vision care trace back to the , with the establishment of Vistakon in 1981 and the launch of the ACUVUE® brand of contact lenses in 1987. As part of Johnson & Johnson's MedTech segment, Johnson & Johnson Vision specializes in comprehensive eye health solutions, encompassing contact lenses for vision correction, intraocular lenses (IOLs) for , and technologies for . Headquartered in , the company operates a global network with manufacturing facilities spanning the , , and to support production and distribution. Employing between 5,000 and 10,000 people worldwide as of 2025, it contributes around $5 billion in annual revenue to the parent corporation in recent years, reflecting its significant scale within the MedTech portfolio. Vision sales reached $5.1 billion in 2024, with operational growth continuing into 2025 (7.7% in Q3). The core mission of Johnson & Johnson Vision centers on advancing vision care innovation to combat prevalent conditions such as refractive errors, cataracts, and dry eye, serving over 44 million people annually and addressing the global burden of visual impairment affecting more than 2 billion individuals. By prioritizing in sustainable eye health technologies, the division aims to prevent and treat vision loss, fostering a healthier future amid rising projections of a 50% increase in by 2030.

Leadership and Global Operations

Johnson & Johnson Vision is led by Company Group Chairman Peter Menziuso, who has over 30 years of experience within the company and oversees the full portfolio encompassing contact lenses, surgical vision solutions, and consumer eye care products. In August 2025, Caroline Blackie was appointed Vice President of Medical Affairs, Vision, and Paul Lisenby as Global Head of , Vision. Key executives include Shawn Millerick as of Vision Care, Americas, responsible for strategy and growth in North and . As part of Johnson & Johnson's MedTech sector, the division reports to the company's Executive Committee, with direct oversight from Tim Schmid, Executive Vice President and Worldwide Chairman of MedTech, and ultimate governance from Chairman and CEO . The organizational structure integrates seamlessly into Johnson & Johnson's decentralized model, enabling agile decision-making while leveraging corporate resources for global scaling. Dedicated R&D centers in —home to the global headquarters for Vision Care—and , , focus on innovation in materials, surgical optics, and eye health diagnostics. Johnson & Johnson Vision maintains a robust global footprint, with operations supporting distribution in more than 60 countries and serving over 44 million patients annually. In 2024, the division generated $5.1 billion in sales, with approximately 41% from the and 59% from international markets, including strong contributions from (23% of overall company sales) and / (15%). Key subsidiaries, such as Johnson & Johnson Vision Care, Inc., drive these efforts by managing regional subsidiaries and adapting products to local regulatory and cultural needs. The supply chain emphasizes efficiency and resilience, with major manufacturing facilities in Jacksonville, Florida, and Limerick, Ireland, producing over 1.7 billion contact lenses annually to meet worldwide demand. Sustainability initiatives are integral, including the introduction of 100% sustainable paper packaging—certified by the Forest Stewardship Council—for all ACUVUE® contact lenses, along with a recycling program that processed over 11 million items, including packaging, in 2023. Strategic partnerships enhance operations and education, such as collaborations with the American Optometric Association (AOA) on patient safety initiatives and the Association for School and College Optometry (ASCO) to promote diversity and eye health awareness in professional training.

Historical Development

Origins and Early Innovations

Johnson & Johnson Vision's roots in contact lens technology trace back to 1959, when was founded in , initially focusing on the production of rigid gas-permeable lenses. By the late 1970s, the company expanded into soft contact lenses, capitalizing on the material's comfort advantages over earlier rigid designs, and established a manufacturing facility in . This shift positioned Frontier as a key player in the emerging soft lens , which had been pioneered industry-wide in the early through innovations but gained commercial traction in the following decade. In 1981, acquired Frontier, rebranding it as Vistakon and accelerating investments in soft lens technology. Under Vistakon, the company introduced extended-wear contact lenses in 1987 with the launch of the ACUVUE brand, enabling overnight use for up to seven days and addressing a major need for patients requiring continuous vision correction, such as those post-cataract surgery. These innovations built on hydrogel formulations like etafilcon A, developed in the , to improve oxygen permeability and wearer comfort while reducing risks associated with prolonged wear. By the mid-1980s, Vistakon's advancements in manufacturing processes, including stabilized soft molding techniques acquired from European partners, enhanced production efficiency and lens quality. Parallel to the contact lens developments, the surgical vision segment originated with Heyer-Schulte Medical Optics, established in the early as a pioneer in ophthalmic implants and medical optics. The company contributed to early (IOL) in the 1970s, producing some of the first FDA-approved IOLs for . In 1974, American Hospital Supply Corporation acquired Heyer-Schulte, renaming its optics division American Medical Optics (AMO) and integrating it into broader ophthalmic efforts focused on refractive and corneal procedures. Key milestones in the and solidified these foundations. In 1987, Vistakon launched the ACUVUE brand, introducing the world's first frequent-replacement soft with a biweekly schedule, which revolutionized hygiene practices and boosted adoption rates among consumers. On the surgical front, AMO expanded its IOL portfolio in the through strategic acquisitions. acquired Iolab Corporation in 1980, which brought advanced IOL designs and strengthened market leadership in solutions. These moves emphasized innovations in corneal and , such as foldable IOLs that minimized incision sizes during procedures. The 2000s brought further growth amid industry consolidation. In 2002, spun off AMO as an independent company, allowing focused expansion in refractive technologies like wavefront-guided systems. AMO's revenues grew steadily, reaching approximately $1 billion by 2010, driven by demand for premium IOLs and surgical consumables. By 2016, ahead of its acquisition by , AMO's annual sales had climbed to around $1.1 billion, reflecting robust performance in global markets despite competitive pressures in . This period highlighted Vistakon's and AMO's complementary strengths, setting the stage for their 2017 integration into a unified vision care entity.

Acquisition by Johnson & Johnson

In September 2016, Johnson & Johnson announced a definitive agreement to acquire Abbott Medical Optics (AMO), a leading provider of surgical and consumer eye care products, for $4.325 billion in an all-cash transaction. The deal was completed on February 27, 2017, following regulatory approvals, at which point AMO was rebranded as Johnson & Johnson Vision, integrating it as a new business unit within Johnson & Johnson's Medical Devices segment. In 2023, as part of Johnson & Johnson's corporate restructuring, the Medical Devices segment was reorganized into Johnson & Johnson MedTech, with Vision continuing as a key division. This acquisition marked Johnson & Johnson's strategic entry into the surgical ophthalmology space, combining AMO's established portfolio in cataract surgery, laser refractive procedures, and consumer eye drops with the company's existing strengths in contact lenses. The primary rationale for the acquisition was to bolster 's position in the fast-growing eye health sector, one of the largest segments in global healthcare, by creating a comprehensive end-to-end offering. Prior to the deal, held a dominant share in the consumer market through its ACUVUE brand, while AMO brought expertise in surgical innovations addressing conditions like cataracts, a leading cause of preventable blindness affecting millions worldwide. The move aimed to leverage synergies between consumer health distribution and advanced surgical technologies, positioning the combined entity to serve patients across the full spectrum of eye needs in a market projected to expand significantly due to aging populations and rising demand for correction. Following the merger, Johnson & Johnson Vision underwent operational rebranding of facilities and streamlined integration of efforts, including the alignment of Vistakon manufacturing and labs—focused on contact lenses—with AMO's surgical R&D capabilities to accelerate innovation in ophthalmic products. This consolidation emphasized shared resources in and technology development, fostering a unified approach to eye solutions. As part of the broader cultural integration, the new division adopted Johnson & Johnson's longstanding values, which prioritize patient needs, ethical practices, and responsible innovation, embedding these principles into daily operations and decision-making to guide ethical advancements in vision care. In the immediate aftermath, the acquisition delivered measurable early impacts, with the surgical vision business contributing approximately 3.1% to Johnson & Johnson's worldwide operational sales growth in the first quarter of 2018 alone. For the full year, the Medical Devices segment, now enhanced by Vision, reported $27 billion in sales, reflecting a 6.3% operational increase over 2017, driven in part by the added revenue from combined product lines. Regulatory milestones followed swiftly, including approvals for integrated ophthalmic technologies in key markets; for instance, advancements in intraocular lenses received clearance in Europe and Asia-Pacific regions starting in 2018, enabling broader global rollout of unified surgical and consumer offerings.

Product Portfolio

Contact Lenses

Vision's contact lens portfolio centers on the ACUVUE® brand family, which includes key offerings like 1-Day ACUVUE® MOIST and ACUVUE® OASYS®. The 1-Day ACUVUE® MOIST, launched in 2007, utilizes etafilcon A, a material designed for daily disposables that incorporates LACREON® Technology to release a cushion of moisture throughout the day, promoting all-day comfort for users with dry eyes. ACUVUE® OASYS®, introduced in 2005, features senofilcon A, a material with high oxygen permeability (Dk/t of 147 for bi-weekly versions), enabling extended wear while reducing dryness through Hydraclear® PLUS technology that stabilizes the tear film. Material innovations in the ACUVUE® lineup emphasize and , with senofilcon A providing Dk/t values exceeding 140 in many models to support corneal health during prolonged use, and etafilcon A offering 58% for daily disposables focused on retention. The brand extends to specialized designs, including multifocal lenses for and toric options for , which incorporate Blink Stabilized® Design to maintain orientation and stability on the eye. All ACUVUE® lenses include built-in UV protection, blocking approximately 97% of UVB rays and 82% of UVA rays across the portfolio. Prescription ranges typically cover from -12.00 to +8.00 diopters and hyperopia, accommodating a broad spectrum of vision needs. In the market, Johnson & Johnson Vision holds a leading position in colored and cosmetic lenses through products like 1-Day ACUVUE® DEFINE®, which enhance natural with subtle iris-inspired patterns and were expanded with new collections around 2020. The company produces over 1.7 billion contact lenses annually, underscoring its scale in daily and specialty wear segments. Clinical studies demonstrate strong comfort performance, with users reporting sustained satisfaction in 16-hour wear trials, where lenses like ACUVUE® OASYS® maintained hydration and reduced end-of-day dryness compared to competitors. A notable 2025 update is the launch of ACUVUE® OASYS MAX 1-Day Multifocal for , the first daily disposable toric multifocal lens combining TearStable™ Technology for enhanced tear film stability and all-day hydration with OptiBlue™ Light Filter to address blue-violet light exposure. This innovation targets presbyopic astigmats, providing clear vision at all distances while prioritizing comfort in extended wear scenarios.

Surgical Vision Products

Johnson & Johnson Vision's surgical portfolio focuses on advanced intraocular lenses (IOLs) and procedural systems for and refractive surgeries, enabling precise corrections for , , and refractive errors. The TECNIS family of IOLs represents a of this lineup, designed to restore a broad range of post- surgery. For instance, the TECNIS IOL, FDA-approved in 2021, is a presbyopia-correcting lens that combines diffractive and refractive to provide continuous from distance to near, featuring a +3.25 D add power for enhanced near capabilities. This IOL addresses common limitations of traditional multifocals by minimizing visual disruptions while extending . Building on this, the TECNIS IOL, launched in the United States in late 2024 and expanded internationally in 2025, offers full visual range correction with exceptional performance in low-light conditions, delivering crisp distance, intermediate, and near through its advanced optic design. Complementing the IOL offerings, surgical devices like the VERITAS Vision System support efficient during procedures. Introduced in 2021 with FDA clearance, this modular platform enhances surgeon control through hybrid fluidics and dual-pump technology (peristaltic and Venturi modes), promoting procedural stability and patient safety; clinical evaluations in 2022 confirmed its effectiveness in reducing surgical times and improving . For refractive applications, the iDESIGN Advanced System enables personalized treatments by integrating topographic and data to map over 1,200 eye measurements, allowing customized patterns that address both lower- and higher-order aberrations. FDA-approved in 2018, it facilitates topo-integrated, wavefront-guided procedures for optimized visual outcomes. In , the VISX S4 , acquired through Advanced Medical Optics (AMO) in 2005, remains a key asset for treating moderate to high . Originally FDA-approved around 2002 for myopic corrections up to -12 D with , it supports wavefront-guided ablations to refine corneal shape precisely. Clinical outcomes for TECNIS IOLs demonstrate strong , with studies showing approximately 90% of patients achieving 20/20 or better uncorrected distance , alongside high satisfaction rates for intermediate and near tasks. Wavefront-guided treatments, such as those using the iDESIGN system with the STAR S4 IR laser, significantly reduce postoperative visual disturbances like halos compared to conventional methods, enhancing quality. Looking to recent advancements, the TECNIS PureSee IOL was showcased at the 2025 European Society of Cataract and Refractive Surgeons (ESCRS) meeting, highlighting its purely refractive extended depth-of-focus design for correction. This IOL delivers spectacle-independent across distances with improved optical quality, including reduced chromatic aberrations through its continuous-power profile, as evidenced by real-world data from multicenter studies presented at the event.

Consumer and Diagnostic Solutions

Johnson & Johnson Vision's consumer and diagnostic solutions focus on non-invasive tools and over-the-counter products to support dry eye management and vision screening, complementing professional eye care practices. These offerings address common ocular surface issues affecting millions worldwide, with an emphasis on improving comfort and early detection without invasive procedures. In 2023, Johnson & Johnson Vision divested its consumer eye health brands, including Blink OTC eye drops, to . A key component of dry eye treatments is the LipiFlow Thermal Pulsation System, acquired through the 2017 purchase of TearScience, Inc., which applies localized heat and intermittent pressure to eyelids for (MGD), the leading cause of evaporative dry eye. Clinical studies demonstrate that LipiFlow improves gland function and reduces symptoms in patients with MGD, providing a 12-minute in-office procedure that enhances tear film stability. The system integrates with consumer-facing education to encourage ongoing ocular surface health maintenance. Diagnostic products include the LipiView II Ocular Surface Interferometer, also from the TearScience integration in 2017, which non-invasively images the tear film layer and with nanometer precision to quantify dry eye severity. This tool supports vision screening by identifying MGD in 60% of wearers and 63% of pre-surgical patients, enabling targeted interventions before procedures like . J&J Vision complements this with the Evaluator, a handheld for assessing expression during exams, aligning with ASCRS guidelines for MGD evaluation. For contact lens care, ACUVUE RevitaLens Multi-Purpose Disinfecting Solution offers all-day hydration and disinfection, with a formula that maintains lens moisture for extended wear comfort. is enhanced through at-home self-care options, such as single-use formulations for on-the-go dry eye relief, and partnerships with major retailers like and for widespread OTC distribution of remaining products. These collaborations ensure broad availability, supporting on allergy-related irritation via integrated dropper designs for precise application.

Recalls and Safety Issues

Major Product Recalls

In 2010, Johnson & Johnson Vision issued a voluntary recall of approximately 100,000 boxes of 1-Day Acuvue and Acuvue TruEye contact lenses due to consumer complaints of eye irritation stemming from equipment failure during the rinsing process at a facility . The issue affected products distributed primarily in and , prompting notifications to distributors and users; no vision damage was reported. The following year, in 2007, Advanced Medical Optics (AMO) recalled its Complete MoisturePlus multipurpose solution after a Centers for Disease Control and Prevention (CDC) investigation linked it to 138 confirmed cases of , a rare but severe corneal infection among soft wearers. The recall was initiated voluntarily as a precaution, with the CDC identifying the solution's inadequate disinfection efficacy against the parasite as the primary risk factor, particularly when combined with poor hygiene practices like showering with lenses. The product was ultimately discontinued, and users were urged to switch to alternative solutions, affecting millions of bottles distributed nationwide and leading to heightened public awareness campaigns on lens care safety. In 2018, Johnson & Johnson Vision conducted a Class II FDA recall (designated Z-2916-2018) for 1-Day ACUVUE MOIST contact lenses due to packaging defects that could compromise sterility, impacting around 806,000 units produced in specific lots. The issue involved potential nonconformities in the blister packaging process, raising concerns about foreign matter or incomplete seals that might lead to eye discomfort or upon insertion. The recall was limited to affected master lots distributed in the U.S., with consumers instructed to discard and replace the lenses; it was officially terminated by the FDA in December 2021 after remediation efforts confirmed resolved manufacturing controls. In June 2025, Johnson & Johnson Vision voluntarily recalled select lots of Acuvue Oasys Max 1-Day Multifocal contact lenses due to a high density of microbubbles that could cause visual disturbances upon insertion. The issue was identified during quality testing and affected products distributed in multiple countries, including ; consumers were advised to return the lenses, with no adverse events reported as of November 2025. Across these incidents, no fatalities were reported, but they resulted in thousands of consumer notifications and product returns, underscoring the importance of vigilant in vision care. The cumulative financial impact on exceeded $100 million, encompassing recall logistics, lost sales, and remediation costs. These events prompted brief regulatory scrutiny, though detailed outcomes are addressed in broader oversight discussions.

Regulatory Responses and Outcomes

Following the 2007 voluntary recall of Complete MoisturePlus multipurpose contact lens solution by Advanced Medical Optics (AMO), acquired by Abbott Laboratories in 2009 and subsequently by Johnson & Johnson Vision in 2017, the U.S. Food and Drug Administration (FDA) issued Form 483 observations to AMO citing failures in quality system regulations, including inadequate reporting of adverse events related to Acanthamoeba keratitis infections and insufficient investigation of manufacturing processes. These actions prompted AMO to enhance its quality controls, though no formal consent decree was imposed specifically on the vision care division at that time. In 2018, Johnson & Johnson Vision initiated a Class II recall of 1-Day Acuvue Moist contact lenses due to packaging nonconformities, leading to FDA oversight but no subsequent warning letters for sterility issues in the division's records. Legal proceedings stemming from the MoisturePlus incident resulted in a settlement in 2011, providing eligible consumers with full cash refunds or coupons for returned products, addressing claims of inadequate warnings about risks. No criminal charges were filed against Johnson & Johnson Vision or its predecessors, but the company has faced ongoing civil litigation related to product safety, with monitoring by regulatory bodies continuing through 2025 to ensure compliance with current good manufacturing practices. In response to these events, Johnson & Johnson Vision implemented enhanced systems aligned with standards for medical devices, focusing on risk-based upgrades across its facilities post-2017 to prevent and defects. The company has also integrated advanced technologies into , contributing to broader operational improvements in defect detection and . By 2025, post-recall audits for ophthalmic products, including intraocular lenses like the TECNIS Eyhance recalled in 2023 for potential unintended toric fiducial marks on the lenses, led to refined sterility assurance protocols under FDA guidance, emphasizing microbial controls in production. Johnson & Johnson Vision expanded collaborations with the International Agency for the Prevention of Blindness (IAPB) to promote global eye care safety standards, supporting initiatives for infection prevention and access to safe vision products. These regulatory engagements have fostered greater transparency, with issuing annual Health for Humanity reports that detail safety metrics and compliance efforts, influencing industry-wide adoption of stringent standards for solutions and ophthalmic devices.

References

  1. [1]
    Vision | J&J MedTech
    Dedicated to solving the vision needs of today while innovating for a healthier sustainable tomorrow. We care for over 44 million people's vision each year.
  2. [2]
    Johnson & Johnson Vision: Clear Vision For You
    We want you to see better. Learn more about eye treatments and solutions designed to meet your eye health and vision needs at every stage of life.Careers · Contact Us · Innovating Eye Health Solutions · News & Media Center
  3. [3]
    https://www.clearvisionforyou.com/en-us/
  4. [4]
    https://www.clearvisionforyou.com/en-us/acuvue-contact-lenses/
  5. [5]
    https://www.clearvisionforyou.com/en-us/cataracts/
  6. [6]
    Our company | Johnson & Johnson
    Johnson & Johnson named to Fortune's 2025 America's Most Innovative Companies list. The company's commitment to developing solutions that tackle the world's ...Our Credo · Our culture of inclusion · Leadership team · Our history
  7. [7]
    Johnson & Johnson Completes Acquisition of Abbott Medical Optics
    Feb 27, 2017 · Johnson & Johnson (NYSE: JNJ) today announced it has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott.Missing: establishment | Show results with:establishment
  8. [8]
    Johnson Johnson Company Profile - GlobalData
    It operates manufacturing units in the US, Europe, Asia-Pacific, Africa, Western Hemisphere (excluding the US), and Latin America. J&J is headquartered in ...Missing: facilities | Show results with:facilities
  9. [9]
    Johnson & Johnson | Vision - LinkedIn
    Headquarters: Jacksonville, FL. Type: Public Company. Locations. Primary. 7500 Centurion Pkwy. Jacksonville, FL 32256, US. Get directions. Employees at Johnson ...
  10. [10]
    jnj-20241229 - SEC.gov
    The Vision franchise achieved sales of $5.1 billion in 2024, representing an increase of 1.5% from 2023. ... Surgical growth was primarily driven by the continued ...<|control11|><|separator|>
  11. [11]
    Peter Menziuso - Johnson & Johnson Vision
    Peter Menziuso, Company Group Chairman at Vision, Johnson & Johnson, leads with over 30 years of experience, driving transformative growth in eye health.
  12. [12]
    J&J Appoints Shawn Millerick as President, Vision Care, Americas
    Dec 2, 2024 · Johnson & Johnson (NYSE: JNJ) has announced the appointment of Shawn Millerick as president, Vision Care, Americas, effective November 11, 2024.
  13. [13]
    Johnson & Johnson Announces Senior Leadership Appointments
    Aug 19, 2025 · The company has also appointed Paul Lisenby as global head of research and development, effective August 4, 2025. Mr. Lisenby brings global ...
  14. [14]
    Our leadership team - Johnson & Johnson
    Dr. Beckerle, age 70, served as Chief Executive Officer of the Huntsman Cancer Institute at the University of Utah from 2006 to 2025.Joaquin Duato · Vanessa Broadhurst · John C. Reed, M.D., Ph.D. · Jennifer Taubert
  15. [15]
    Johnson & Johnson's Organizational Structure [Interactive Chart]
    Johnson & Johnson's org structure has been designed to support the company's operations through defined departments with clear reporting hierarchies.Missing: Vision | Show results with:Vision
  16. [16]
    Johnson & Johnson Vision is Grounded and Growing in Jacksonville
    Since then, Johnson & Johnson Vision which has its global headquarters based in Jacksonville has continued to innovate and prosper in the region to become ...<|control11|><|separator|>
  17. [17]
    R&D Scientist, Groningen | Johnson & Johnson Careers
    Oct 17, 2025 · Johnson & Johnson is currently seeking a Staff R&D Scientist for our JnJ Surgical Vision located in Groningen, Netherlands. JnJ Surgical Vision ...
  18. [18]
    [PDF] Johnson & Johnson 2024 Annual Report
    Mar 4, 2025 · Total employee obligations. 7,847. 7,687. Less current benefits payable ... Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) ...<|control11|><|separator|>
  19. [19]
    Subsidiaries - SEC.gov
    Johnson & Johnson Vision Care, Inc. Florida ; Joint Medical Products Corporation. Delaware ; JOM Pharmaceutical Services, Inc. Delaware ; LifeScan, Inc. California.
  20. [20]
    Sustainability at Johnson & Johnson Vision - ABDO
    To date, we have saved 42,000 tons of CO2 annually through renewable and energy efficient programmes*[iii]. Similarly, we are passionate about reducing waste.
  21. [21]
    Johnson & Johnson Vision's three sustainability focuses - AOP
    Jun 7, 2023 · “It has evolved year by year, and effectively means that we've recycled more than 11 million lenses, foils, packaging and otherwise – and has ...
  22. [22]
    CooperVision joins the Healthcare Alliance for Patient Safety
    The American Optometric Association, CooperVision and Johnson & Johnson have joined forces to create the Healthcare Alliance for Patient Safety.
  23. [23]
    ASCO Partners with Johnson & Johnson Vision to Bring More ...
    Mar 11, 2022 · “ASCO is excited to be teaming up with Johnson & Johnson Vision in our efforts to address the diversity issues in optometry today,” says Dr.
  24. [24]
    Made in Jax: Contact lenses roll out by the thousands at Johnson ...
    The company's roots go back to Buffalo, N.Y., where Frontier Contact Lenses was formed in 1959. It built a plant in Jacksonville in the 1970s. Johnson & ...
  25. [25]
    Marking a Milestone: 25 Years of Soft Contact Lenses
    Mar 1, 1996 · In 1981, Johnson & Johnson acquired Frontier Contact Lenses, Inc., a hard lens manufacturer that had started producing soft lenses in the late- ...
  26. [26]
    A History of Contact Lens Innovation
    Sep 1, 2007 · Acuvue lenses got their start at Frontier Contact Lens Company, a small firm that began making hard contact lenses in Buffalo, NY, in the 1950s.
  27. [27]
    HISTORY OF CONTACT LENSES - Contact Lens Spectrum
    Feb 1, 2022 · In 1981, JNJ purchased Jacksonville-based Frontier Contact Lens, which manufactured lathe-cut rigid and soft lenses and was owned by Dr. Allen ...
  28. [28]
    Material Gains: 50 Years of the Soft Contact Lens
    Apr 15, 2021 · The first soft contact lens was approved by the Food and Drug Administration 50 years ago, the market has grown exponentially.
  29. [29]
    [PDF] Industry's Contribution to Refractive Surgery
    Advanced Medical Optics, Inc.'s (AMO) reputation for innovation began more than three decades ago as the ophthalmic research arm of Heyer-Schulte Medical.
  30. [30]
    Advanced Medical Optics, Inc. | Encyclopedia.com
    AMO's history began with the history of Allergan Inc., an Irvine, California-based company that matured from a small ophthalmic laboratory founded in 1950 ...
  31. [31]
    Replaceable Lenses, Irreplaceable Progress
    Apr 15, 2021 · After three years of development, Vistakon launched the seminal Acuvue lens in 1987 ... launched their own frequent replacement lenses in the now- ...
  32. [32]
    20 Years of Contact Lenses | Contact Lens Spectrum
    Jun 1, 2006 · In 1987 Johnson & Johnson/Vistakon introduced its Acuvue Disposalens system, and in 1988 Bausch & Lomb added Sequence while CIBA Vision added ...
  33. [33]
    One on One with Dan Myers - Healio
    Sep 15, 1999 · We formed the team that acquired Cooper Vision Pharmaceuticals for Iolab in 1986. We assimilated the drug business into the old Iolab, which at ...
  34. [34]
    [PDF] ALLERGAN 2004 ANNUAL REPORT
    (n) Duplicate operating expenses of $4.4 million related to the spin-off of Advanced Medical Optics, net of income of $1.5 million from a partnering agreement.Missing: 2010-2016 | Show results with:2010-2016
  35. [35]
    Abbott selling Medical Optics business for $4.3BN
    Sep 19, 2016 · The business unit started out more than three decades ago as the ophthalmic research division of the Heyer-Schulte Medical Optics Center (HSMOC) ...Missing: formation | Show results with:formation
  36. [36]
    Johnson & Johnson Announces Agreement to Acquire Abbott ...
    Sep 16, 2016 · Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, ...
  37. [37]
    J&J's Recent Move: A Visionary Acquisition Or An Optical Illusion?
    Sep 26, 2016 · The acquisition of Abbott's Optice business is a step in this direction. The total world wide vision-care market is estimated at $68 billion ...
  38. [38]
    Johnson & Johnson Vision Is Created With Completion of J&J's ...
    Mar 1, 2017 · Johnson & Johnson Vision Is Created With Completion of J&J's Acquisition of AMO ... Other capabilities (such as R&D, supply chain, finance ...Missing: integration Vistakon
  39. [39]
    Our Credo - Johnson & Johnson
    Sep 27, 2023 · The values that guide our decision-making are spelled out in Our Credo. Put simply, Our Credo challenges us to put the needs and well-being ...
  40. [40]
    Johnson & Johnson Reports 2018 First-Quarter Results
    Apr 17, 2018 · ... acquired surgical vision business which contributed 3.1%, to worldwide operational sales growth. Excluding the net impact of acquisitions ...Missing: revenue boost
  41. [41]
    J&J posts $27B in 2018 medical device sales in slight bump
    Jan 22, 2019 · J&J's medtech business contributed to overall sales of $81.6 billion in 2018 sales, up 6.3% operationally over 2017.Missing: boost | Show results with:boost
  42. [42]
    Johnson & Johnson Vision Announces The Approval Of TECNIS ...
    May 25, 2021 · The TECNIS Synergy™ IOL was first launched in Europe and Asia Pacific in 2019 and is currently available in Latin America and Canada. The full ...
  43. [43]
    1-DAY ACUVUE® MOIST with LACREON® Technology
    A long-lasting cushion of moisture for 20+ hours. Unbeaten comfort + In 14 clinical studies when compared to other hydrogel daily disposable contact lenses.
  44. [44]
    1-DAY ACUVUE® MOIST 90-pack | Costco Contacts Online
    90-day returns$63.87 per box · Material: Etafilcon A · Wear & Replace Schedule: Daily Disposable · Water Content: 58% · FSA Eligible · Product Safety Information · Item may be ...<|separator|>
  45. [45]
    ACUVUE® OASYS Contact Lenses
    UV-blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV ...Acuvue Oasys · Acuvue Oasys for Astigmatism · Acuvue Oasys 1-Day · Oasys 1 DayMissing: diopters | Show results with:diopters
  46. [46]
    https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-2018-first-quarter-results
  47. [47]
    ACUVUE® OASYS 1-Day with HydraLuxe® Technology | J&J Vision
    Lens specifications ; Dk/t $ (edge corrected). 121 x 10 -9 (-3.00D) ; Water Content. 38% ; UV Blocking – Class 1 · ~99.9% UVB and ~96% UVA ; Center thickness at - ...
  48. [48]
    Benefits of UV Protection & Blocking | ACUVUE® Contacts
    ACUVUE contact lenses are the only major brand which blocks at least 97% of UVB and 82% of UVA rays, as standard across the entire product line.Missing: diopters | Show results with:diopters
  49. [49]
    ACUVUE OASYS® with HYDRACLEAR® PLUS 2-Week
    These lenses offer unbeaten comfort, are the #1 selling brand, have built-in UV protection, and use HYDRACLEAR® PLUS technology with a wetting agent.Missing: 16- | Show results with:16-
  50. [50]
    J&J Vision debuts new try-it augmented reality tech application for ...
    Jul 29, 2020 · The Define brand lenses accentuate eye color in part by outlining the limbal ring, which is the circular edge of the iris, versus traditional ...
  51. [51]
    Real-Time Changes in the Comfort of a Toric, Monthly, Soft Contact ...
    Dec 17, 2024 · The present work set out to determine if this toric 30-day replacement daily wear CL provides adequate comfort to be worn for a 16-hour day. The ...
  52. [52]
    ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM
    Jun 23, 2025 · Later this summer, the ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lens will launch in both the U.S. and Canada, making the ACUVUE OASYS MAX ...
  53. [53]
    ACUVUE® OASYS MAX 1-DAY MULTIFOCAL for ASTIGMATISM
    These lenses provide clear vision at all distances, in all lighting, all-day comfort, exceptional stability, and address issues for people with astigmatism.
  54. [54]
    Clinical performance of a hybrid presbyopia-correcting...
    TECNIS Synergy (Johnson & Johnson Vision), model ZFR00V, is designed to provide an increased range of vision for distance, intermediate, and near tasks.
  55. [55]
    Johnson & Johnson Rolls Out New TECNIS Odyssey Next ...
    Sep 30, 2024 · The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3†.
  56. [56]
    Launches New TECNIS Odyssey Next-Generation Intraocular Lens ...
    Jun 17, 2025 · TECNIS Odyssey IOL provides crisp and clear vision, allowing patients to see with clarity at every distance 6 - whether they are reading, driving or engaging ...
  57. [57]
    [PDF] Johnson & Johnson Surgical Vision, Inc. Amanda Houston Senior ...
    Mar 12, 2021 · The VERITAS™ Phacoemulsification Console is a modular ophthalmic microsurgical system for cataract surgery, under Class II regulation.Missing: 2022 | Show results with:2022
  58. [58]
    Clinical Performance and Surgeon Acceptability of a New Dual ...
    Aug 6, 2022 · The VERITAS Vision System was designed to address three critical areas: patient safety, surgeon efficiency, and surgeon comfort. The overall ...Introduction · Figure 1 · Primary OutcomeMissing: AI- assisted
  59. [59]
    iDESIGN™ Refractive Studio | J&J Vision Professional
    Topo-integrated, wavefront-guided treatment planning for personalization. Expanded diagnostic capabilities. Topographic maps, views and summary metrics.
  60. [60]
    FDA Approves the Next Generation of Customized LASIK Treatment ...
    Jun 18, 2018 · Johnson Johnson Vision announced today the U.S. Food and Drug Administration (FDA) approval of the iDESIGN Refractive Studio , making it the ...
  61. [61]
    [PDF] Advanced Medical Optics Corporate Profile
    AMO Completes Acquisition of VISX,. Inc. (5/31/05). AMO Acquires Quest Vision ... FDA Approves STAR S4 IR™ Laser. System for Treatment of High Myopia with ...
  62. [62]
    [PDF] VISX STAR S4 Excimer Laser System and WaveScan
    Date of Notice of Approval. May 23, 2003 to Applicant: The STAR Excimer Laser was originally approved on March 27, 1996, under PMA P930016, ...Missing: AMO | Show results with:AMO
  63. [63]
    Clinical Outcomes of TECNIS Toric Intraocular Lens Implantation ...
    Nov 17, 2014 · The TECNIS toric IOLs successfully reduce ocular astigmatism and are a safe and effective treatment for cataract patients with corneal astigmatism.
  64. [64]
    Starburst Phenomenon in Wavefront–Guided LASIK Compared With ...
    Wavefront guided LASIK is thought to reduce night vision symptoms of starbursts, glare, and halos. In this study, we objectively measure and compare ...
  65. [65]
    Johnson & Johnson Showcases New Data for TECNIS™ IOLs at ...
    Sep 4, 2025 · Johnson & Johnson Showcases New Data for TECNIS™ IOLs at ESCRS 2025 · J&J Vision IOL Innovation Summit: TECNIS Odyssey™ IOL & TECNIS PureSee™ IOL ...
  66. [66]
    Optical and Visual Outcomes of a New Refractive Extended Depth of ...
    Apr 1, 2025 · The TECNIS PureSee IOL provided good distance optical and visual quality, and a clinically determined extended depth of field of approximately 2.00 D.
  67. [67]
    Johnson & Johnson Presents New Real-World Data for TECNIS ...
    Sep 14, 2025 · Johnson & Johnson Presents New Real-World Data for TECNIS PureSee™ IOL at ESCRS 2025 · Strong visual outcomes across distances: Patients achieved ...Missing: aberration | Show results with:aberration
  68. [68]
    Ocular Surface | Johnson & Johnson Vision Professional
    Elevate your eye care practice with valuable insights and resources on ocular surface health. Stay informed and optimize patient outcomes at ...Missing: division | Show results with:division
  69. [69]
    LipiFlow® Thermal Pulsation System: A New Dry Eye Treatment for ...
    The LipiFlow Thermal Pulsation System, which uses a cutting-edge device to heat up and massage away the blockage in just 12 minutes, right in your eye doctor's ...
  70. [70]
    LipiFlow® thermal pulsation system | J&J Vision Professional
    The TearScience LipiFlow System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the ...Missing: tools | Show results with:tools
  71. [71]
    LipiView® II ocular surface interferometer | J&J Vision Pro
    TearScience™ LipiView™ II Reporting offers real-time visualization. Lipid Layer Thickness (LLT) Evaluation with Nanometer Accuracy Presents lipid layer ...Missing: integration 2017
  72. [72]
    Johnson & Johnson Vision Announces TearScience LipiScan and ...
    Nov 9, 2017 · The LipiFlow® System is a best-in-class medical device treatment for MGD shown to improve mean gland function and dry eye symptoms. The efficacy ...
  73. [73]
    Meibomian Gland Evaluator™ | J&J Vision Professional
    Improve patient care with our advanced Meibomian gland eye exam tool. Accurately assess and diagnose eye conditions for effective treatment strategies.Missing: iCare | Show results with:iCare
  74. [74]
    Abbott to Sell Abbott Medical Optics to Johnson ... - Press Releases
    Sep 16, 2016 · Abbott (NYSE: ABT) announced today that it will sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash.
  75. [75]
    ACUVUE ® RevitaLens Multi-Purpose Disinfecting Solution
    ACUVUE RevitaLens Multi-Purpose Disinfecting Solution delivers exceptional disinfection against harmful germs and bacteria and helps with all-day comfort.
  76. [76]
    https://www.jnj.com/innovation/lipiflow-thermal-pulsation-system-a-new-dry-eye-treatment
  77. [77]
    Recalled Eye Drops Highlight Deficiencies in Regulatory Oversight
    Jan 31, 2025 · The last 2 years have brought about a spate of ophthalmic OTC treatment recalls, prompted by concerns ranging in severity from potential sterility issues.
  78. [78]
    Johnson & Johnson's Quality Catastrophe - Bloomberg.com
    Mar 31, 2011 · Over the last 15 months, the company has also recalled contact lenses, syringes filled with prescription medications, hernia devices, and other ...
  79. [79]
    J&J recalls contact lenses after complaints - NJ.com
    Aug 23, 2010 · ... plant and another in Las Piedras, Puerto Rico. They have involved problems ranging from contamination with bacteria and a nauseating smell ...
  80. [80]
    Acanthamoeba Keratitis Multiple States, 2005--2007 - CDC
    Jun 1, 2007 · This report summarizes recent preliminary results of that investigation, which, indicated an association with AK in soft contact lens wearers ...
  81. [81]
    National Outbreak of Acanthamoeba Keratitis Associated with ... - CDC
    This investigation of a national AK outbreak identified use of a single contact lens solution as the primary risk factor for infection. AMOCMP is a multipurpose ...
  82. [82]
    Class 2 Device Recall Johnson and Johnson Vision Care 1 Day ...
    Class 2 Device Recall Johnson and Johnson Vision Care 1 Day ACUVUE MOIST ; Terminated on December 06, 2021 · Z-2916-2018 · 80654 · K062614 · Lenses, soft contact, ...
  83. [83]
    Potentially hazardous eye care products recalled nationwide
    May 12, 2025 · All of these products were distributed by AvKARE, of Pulaski, TN, and all were distributed between May 26, 2023, and April 21, 2025.
  84. [84]
    https://www.nj.com/business/2010/08/jj_recalls_contact_lenses_afte.html
  85. [85]
    [PDF] Advanced Medical Optics June 2007 483 - FDA
    Jun 25, 2007 · a) The voluntary recall of Complete® MoisturePlus™ contact lens solutions products. b) The decision to readdress MDR reportability for comeal ...
  86. [86]
    AMO Complete MoisturePlus Class Action Lawsuit Settlement
    AMO will give a 100% cash refund for every bottle of Complete MoisturePlus that ...Missing: Moisture Plus
  87. [87]
    Complete MoisturePlus Contact Solution Class Action Settlement
    Nov 29, 2011 · AMO reaches class action lawsuit settlement over 2007 parasite scare related to its Complete MoisturePlus contact solution.<|control11|><|separator|>
  88. [88]
    [PDF] Position on Quality and Compliance
    Establishing the Quality and Compliance Vision ... For additional information on the implementation of international standards for GMPs, see our Johnson & Johnson.Missing: 2017 | Show results with:2017
  89. [89]
    Class 2 Device Recall TECNIS Eyhance IOL - accessdata.fda.gov
    Aug 3, 2023 · The TECNIS Eyhance IOL was recalled due to a potential for unintended toric fiducial marks on the intraocular lenses.
  90. [90]
    IAPB & J&J Vision Partner to Advocate for Eye Health
    Johnson & Johnson Vision collaborates with the International Agency for the Prevention of Blindness (IAPB) to improve eye health advocacy worldwide.
  91. [91]
    [PDF] johnson-johnson-2024-health-for-humanity-report.pdf
    J&J employees and retirees also contribute financial resources to nonprofit organizations. Through the Matching Gifts Program, the Johnson & Johnson Foundation, ...